IHE iShares U.S. Pharmaceuticals ETF

Mentions (4)

• Newszacks.com·21d ago·Neutral

  Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)? The iShares U.S. Pharmaceuticals ETF (IHE) was launched on May 1, 2006, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Pharma segment of the equity market.

  View source ↗
• Newsseekingalpha.com·24d ago·Negative

  IHE: Innovation Supports The Outlook, Valuation Limits Conviction iShares U.S. Pharmaceuticals ETF offers concentrated exposure to US pharma, dominated by Johnson and Johnson (22.5%) and Eli Lilly and Company (20.5%). IHE benefits from structural growth in obesity therapies, robust drug pipelines, and demographic tailwinds but faces high concentration risk. Short-term catalysts include LLY's earnings momentum, FDA drug approvals, sector M&A activity, and potential interest rate improvements.

  View source ↗
• Newsseekingalpha.com·25d ago·Neutral

  IHE: Large-Cap Pharma Cools After A Hot Summer I issue a hold rating on the iShares US Pharmaceuticals ETF due to fair valuation and mounting near-term headwinds. IHE's portfolio is highly concentrated, with 43% in JNJ and LLY and top 10 holdings totaling 76%. Technical trends have turned concerning, with a recent breach of trendline support and a possible 10% correction to $97 likely through October.

  View source ↗
• Newsfool.com·45d ago·Negative

  Pharma ETF or Biotech ETF: Which Matches Your Investing Mindset? IHE delivered 53.2% returns over one year with lower volatility and a 0.37% expense ratio, while PBE's quantitative biotech strategy carries higher risk.

  View source ↗